News

He developed several compounds, kinase inhibitors for clinical trials including sunitinib, which was approved by FDA for the treatment of renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumor in 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications. He was member of several national and international biotechnology organizations and editor of Current Signal transduction Therapy and of Current Opinion in Molecular Therapeutics and some other journals. He founded Vichem in 1999 to develop kinase inhibitor library and a hit-finding technology called Nested Chemical Library™. He has recently developed at Vichem the DriverHit Library™ for inhibiting the signaling pathways activated by cancer driver genes or mutated tumor suppressor genes. CycloLab has been collaborating with Vichem for years. We have been working together in the Marie Curie Initial Training (CyclonHIt) project.

We will miss him.

 

To learn more on his activity see:

https://en.wikipedia.org/

BACK TO NEWS